@FiercePharma: AstraZeneca beats back would-be Crestor copycats. Report | Follow @FiercePharma
> Denmark's Lundbeck said it would sell off a handful of products to Italy's Recordati for $80 million up front and a possible $20 million in additional payments. Report
> The FDA once again delayed its decision on Amarin's ($AMRN) market exclusivity for its blood-lipid drug Vascepa. Report
> Europe's drug-review committee has recommended against approval of Vanda Pharmaceuticals' ($VNDA) antipsychotic drug Fanaptum. Report
> Prominent pediatricians and public health experts warn that banning the vaccine preservative thimerosal would interfere with immunization campaigns in developing countries. Report (sub. req.)
> Mayne Pharma is raising $19 million to fund the acquisition of GlaxoSmithKline's ($GSK) morphine-based pain drug Kapanol. Report (sub. req.)
@FierceMedDev: Malaysia is working hard to diversify its med device manufacturing base. International competition is increasing. News | Follow @FierceMedDev
@MarkHFierce: Barron's sees J&J poised for major growth, but NOT through its med device business. More | Follow @MarkHFierce
@DamianFierce: Quintiles is handling recruitment and "clinical services" for AstraZeneca's novel depression drug. Story | Follow @DamianFierce
> Orthofix resolves Medicare kickback case. News
> Amarantus licenses Alzheimer's blood Dx. Story
> Bioresorbable stents hit India, but most patients can't afford them. Article
Biotech News
@FierceBiotech: Baxter joins Big Pharma funds on $38M B round for Naurex antidepression R&D. Article | Follow @FierceBiotech
@JohnCFierce: Troubled Intercell (bought Iomai) throws in the towel, signs off on merger deal with Vivalis. More | Follow @JohnCFierce
@RyanMFierce: Dang. Another biotech deal this busy am. Naurex nails down $38M B round led by Baxter for depression candidate. Release | Follow @RyanMFierce
> Tranzyme takes a beating after scuttling another drug study. Report
> Apple Tree inks $305M drug deal to back biotech portfolio game plan. News
> Phenex grabs $135M discovery deal with J&J. Item
Biotech IT News
> How lessons from iPhone's Siri aid biological exploration. Story
> GlaxoSmithKline dials up Vodafone for mobile tech alliance. Article
> Russian billionaire backs 23andMe in $50M round. News
> Could computers predict the next big Alzheimer's drug? Report
CRO News
> Patheon closes $255M Banner deal. Item
> Charles River projects a modest 2013, slides on the Street. Story
> Catalent inks biosimilar deal with Japanese CMO. Article
> Quintiles recruiting for AstraZeneca's novel depression drug. News
> Warnex closes bioanalytics sale, exits CRO biz. Report
And Finally... A longtime proponent of opioid painkillers is backpedaling on early recommendations as new research suggests a higher risk of addiction than previously thought. Report (sub. req.)